Business Wire · Jul 2025
MoU to industrialize and scale Sensible’s cell-based mRNA platform, with the goal of enabling clinical-grade production by 2026 and expanding manufacturing support across the US, UK, and Europe.
Unlocking the next generation of mRNA medicines
Company research
Public company, workplace, funding, and market signals
Overview
Sensible Biotechnologies is a cell-based mRNA therapeutics platform company building living-cell manufacturing for high-purity, low-immunogenicity mRNA for pharma/biotech partners. Public sources conflict on headquarters (Claymont, Delaware vs Oxford, UK); the clearest operating footprint is Boston, Oxford, and Bratislava.
Primary product
Cell-based mRNA design, optimization, and manufacturing platform
Founded
2021
Headquarters
Claymont, Delaware, United States
Team size
11-50 employees
Industry
Biotechnology Research
Sub-industry
cell-based mRNA therapeutics
Offices
Boston, Massachusetts, United States
Open Positions
0 jobs at Sensible Biotechnologies
No open positions
Check back later for new openings